https://en.genomics.cn/en-news-278-6946.html

Beijing, June 7 – Mr. Cai Lei, Founder and CEO of the "Gradually Healing Mutual Aid Home" platform, and Dr. Yin Ye, CEO and Executive Director of BGI Group, announced their collaboration to create a multi-omics research joint laboratory to accelerate the research of ALS.

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that causes the progressive degeneration of nerve cells in the spinal cord and brain. The establishment of the joint laboratory is expected to deepen the cooperation between the two parties, accelerate progress in the current multi-omics research field of ALS, and provide new insights into the diagnosis of ALS, quantitative assessment of disease progression, and the discovery of intervention targets.

In the opening speech at the signing ceremony, Mr. Cai, who has ALS, expressed his deep hopes for this cooperation. He praised Dr. Yin and the BGI team for their substantial scientific research assistance. The establishment of the joint laboratory will enable both parties to further integrate genomics, spatiotemporal omics, and other multi-omics data, including proteomics, metabolomics, and immunomics, with the aim of achieving breakthroughs in the treatment of rare and difficult diseases.

Mr. Cai emphasized that the vision of this cooperation goes beyond academic achievements and commercial interests. Both parties are committed to building a more open data-sharing platform, attracting more partners, jointly improving the scientific research landscape, and pursuing long-term social value. He noted that this cooperation model will benefit both ALS patients and other rare disease groups.

In the future, through the combination of BGI's world-leading whole-genome sequencing and spatiotemporal omics technologies, real samples will be directly linked to clinical pathology, and drug targets can be identified more efficiently. This will provide critical insights into genetic risk factors.